Vaccine group Gavi seeks $9 billion to immunise world's poorest children
Adds finalised amount to headline and story, updates throughout
By Jennifer Rigby
LONDON, June 20 (Reuters) -The global vaccine organisation Gavi wants $9 billion from governments and foundations to fund immunisation efforts in the world’s poorest countries over five years, it said on Thursday.
The amount was finalised at a meeting in Paris, where donors also began announcing commitments for the organisation's plan for 2026-2030. Gavi said it had already raised $2.4 billion of the total with months more fundraising to go, including $1.58 billion from the United States.
A separately funded $1.2 billion scheme to boost vaccine production in Africa, the African Vaccine Manufacturing Accelerator, also launched.
Gavi helps low-income countries buy vaccines to protect against killer diseases. Around one billion children have been immunised as a result of Gavi’s work since 2020.
Gavi Chief Executive Sania Nishtar said the group aims to move more quickly and offer more vaccines. This will include expanding a malaria vaccine roll-out, which began in Cameroon this year, as well as catching up on routine programmes for diseases like measles, which were set back by the COVID-19 pandemic.
The global vaccine alliance wants to reach “the highest number of children, covering them against the widest number of diseases ... in the shortest possible time,” Nishtar told Reuters in an interview on Wednesday, ahead of the meeting.
The organisation wants to reach 500 million children in the next five years, including 50 million children with the malaria vaccine.
Gavi board documents had suggested the alliance needs up to $11.9 billion for its work from 2026 on. The remaining money will come from leftover COVID-19 financing and some financial instruments the organization has in place, Nishtar said, although she acknowledged it was a very challenging time for global health, with aid budgets stretched worldwide by demands from conflicts to climate change.
“Gavi has never had to make trade-offs,” she said. “On the one hand, there is a wide portfolio of vaccines available. On the other hand, we’re looking at an environment where donors are resource constrained.”
But she said she was cautiously optimistic that the organisation would raise the amount needed.
Gavi also plans to further expand its work in the coming years, for example by setting up an mpox vaccine stockpile. It is also likely to add a dengue vaccine to its programme as climate change puts more countries at risk of outbreaks. It will also establish a "day zero" $500 million pandemic response fund for quick action on major outbreaks.
Reporting by Jennifer Rigby; Editing by Cynthia Osterman and Mark Potter
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
